• 1
    Strand CL, Shulman JA. Bloodstream infections: laboratory detection and clinical considerations. Chicago: American Society of Clinical Pathology Press, 1998.
  • 2
    Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781805.
  • 3
    Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis. 2000; 31: 188189.
  • 4
    Duthie R, Denning DW. Aspergillus fungemia: report of 2 cases and review. Clin Infect Dis. 1995; 20: 598605.
  • 5
    Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001; 7( Suppl 2): 824.
  • 6
    Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis. 2002; 34: 14151417.
  • 7
    Anaissie E, Bodey GP, Kantarjian H, et al. New spectrum of fungal infections in patients with cancer. Rev Infect Dis. 1989; 1: 369378.
  • 8
    Revankar SG, Patterson JE, Sutton DA, Pullen R, Rinaldi M. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis. 2002; 34: 467476.
  • 9
    Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001; 17: 531570.
  • 10
    Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation: Scedosporiasis and recent advances in antifungal therapy. Transplant Infect Dis. 2002; 4: 212217.
  • 11
    Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Manual of clinical microbiology. Washington, DC: American Society for Microbiology, 1995.
  • 12
    Henslee-Downey JP, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood. 1997; 89: 38643872.
  • 13
    Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001; 28: 873878.
  • 14
    Girmenia C, Nucci M, Martino P. Clinical significance of Aspergillus fungemia in patients with haematological malignancies and invasive aspergillosis. Br J Haematol. 2001; 114: 9398.
  • 15
    Gucalp R, Ciobanu N, Sparano J, Motyl M, Carlisle P, Wiernik PH. Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. Cancer. 1991; 68: 18421844.
  • 16
    Morrison VA, Haake RJ, Weisdorf DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine. 1993; 72: 7889.
  • 17
    Sayer HG, Longton G, Bowden R, Pepe M, Storb R. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood. 1994; 84: 13281332.
  • 18
    Safdar A, Armstrong D. Infections in patients with neoplastic diseases. In: ShoemakerWC, GrenvikM, AyersSM, HolbrookPR, editors. Textbook of critical care. Philadelphia: WB Saunders, 2000: 715726.
  • 19
    White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med. 2000; 161: 723729.
  • 20
    Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996: 33: 2332.
  • 21
    Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev. 2002; 15: 465484.
  • 22
    Fontaine T, Simenel C, Dubreueq G, et al. Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall. J Biol Chem. 2001; 275: 2759427607.
  • 23
    Kretschmar M, Buchheidt D, Hof H, Nichterlein T. Galactomannan enzyme immunoassay for monitoring systemic infection with Aspergillus fumigatus in mice. Diag Microbiol Infect Dis. 2001; 41: 107112.
  • 24
    Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J. 1996; 15: 232237.
  • 25
    Verweij PE, Donnelly JP, De Pauw BE, Meis JFGM. Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patients. Rev Med Microbiol. 1996; 7: 105113.
  • 26
    Maertens J, Verhaegen J, Demuynck H, et al. Autopsy controlled prospective evaluation of serial screening for circulating galactomannan by sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol. 1999; 37: 32233228.
  • 27
    Reiss E, Tanaka K, Bruker G, et al. Molecular diagnosis and epidemiology of fungal infections. Med Mycol. 1998; 36: 249257.
  • 28
    Loeffler J, Henke H, Hebart H, et al. Quantification of fungal DNA by using fluorescence resonance energy transfer and light cycle system. J Clin Microbiol. 2000; 38: 586590.
  • 29
    Loeffler J, Hebart H, Cox P, Flues N, Schumacher U, Einsele H. Nucleic acid sequence-based amplification of Aspergillus RNA in blood samples. J Clin Microbiol. 2001; 39: 16261629.
  • 30
    Pryce TM, Kay ID, Palladino S, Heath CH. Real-time automated polymerase chain reaction (PCR) to detect Candida albicans and Aspergillus fumigatus DNA in whole blood from high-risk patients. Diag Microbiol Infect Dis. 2003; 47: 487496.